What amount sold does 60 DEGREES PHARMACEUTICALS, INC. report in Form D filings?

The latest linked filings report $3.9M sold across 3 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was 60 DEGREES PHARMACEUTICALS, INC.'s most recent SEC filing?

60 DEGREES PHARMACEUTICALS, INC.'s most recent Form D filing was on 2025-02-12.

How many investors does 60 DEGREES PHARMACEUTICALS, INC. have?

The most recent Form D filing lists 4 investor(s).

60 DEGREES PHARMACEUTICALS, INC.

CIK: 0001946563·Pharmaceuticals·WASHINGTON, DC·Corporation·Founded 2022

Reported Sold

$3,873,005

Total Filings

Identified Offerings

Last Filed

Feb 12, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Feb 12, 2025Form D — New notice

Reported sold: $1,075,003 · Target: $1,075,003

Rule 506(b)·4 investors

Feb 11, 2025Form D — New notice

Reported sold: $1,043,002 · Target: $1,043,002

Rule 506(b)·4 investors

May 24, 2023Form D — New notice

Reported sold: $1,755,000 · Target: Indefinite

Rule 506(b)·10 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$380,530

Amendment Rate

Latest reported sold across 3 identified offerings

$3,873,005

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Geoffrey S. Dow

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Feb 12, 2025	New	$1,075,003	$1,075,003	4
Feb 11, 2025	New	$1,043,002	$1,043,002	4
May 24, 2023	New	Indefinite	$1,755,000	10

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Telemachus Therapeutics, Inc.

Pharmaceuticals

Offering target: $1,500,000

Filed Oct 28, 2026